{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:48:58Z","timestamp":1768636138491,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/jcp.0b013e318204825b","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T10:39:24Z","timestamp":1293705564000},"page":"86-91","source":"Crossref","is-referenced-by-count":49,"title":["Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia"],"prefix":"10.1097","volume":"31","author":[{"given":"Deanna L.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Linthicum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Patricia","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi J.","family":"Wehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn A.","family":"Huestis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Heishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly R.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"11","key":"R1-16-20210128","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1525-1497.2006.00563.x","article-title":"Medical comorbidity in women and men with schizophrenia: a population-based controlled study.","volume":"21","author":"Carney","year":"2006","journal-title":"J Gen Intern Med"},{"issue":"3","key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0920-9964(01)00256-0","article-title":"Changes in body mass index for individuals with and without schizophrenia, 1987-1996.","volume":"55","author":"Homel","year":"2002","journal-title":"Schizophr Res"},{"issue":"14","key":"R3-16-20210128","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","article-title":"Prevalence and trends in obesity among US adults, 1999-2000.","volume":"288","author":"Flegal","year":"2002","journal-title":"Jama"},{"issue":"1","key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"issue":"2","key":"R5-16-20210128","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4088\/PCC.v06n0205","article-title":"Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia.","volume":"6","author":"Kato","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"1","key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.","volume":"83","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"issue":"2","key":"R7-16-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4088\/JCP.v66n0203","article-title":"Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey.","volume":"66","author":"Susce","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"R8-16-20210128","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4088\/JCP.v65n0517","article-title":"Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs.","volume":"65","author":"Lamberti","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R9-16-20210128","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1192\/bjp.184.47.s64","article-title":"Diabetes mellitus and schizophrenia: historical perspective.","volume":"47","author":"Kohen","year":"2004","journal-title":"Br J Psychiatry Suppl"},{"issue":"6","key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease.","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am Heart J"},{"issue":"4","key":"R11-16-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/070674379103600401","article-title":"Mortality in a cohort of patients with schizophrenia: a record linkage study.","volume":"36","author":"Newman","year":"1991","journal-title":"Can J Psychiatry"},{"issue":"18","key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMcp0801652","article-title":"Clinical practice. Nonsurgical management of obesity in adults.","volume":"358","author":"Eckel","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/schbul\/sbp115","article-title":"The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.","volume":"36","author":"Dixon","year":"2010","journal-title":"Schizophr Bull"},{"issue":"1","key":"R14-16-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"3","key":"R15-16-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12264-009-0112-3","article-title":"The endocannabinoid system: a new pharmacological target for obesity treatment?","volume":"25","author":"Hu","year":"2009","journal-title":"Neurosci Bull"},{"issue":"1","key":"R16-16-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2008.09.001","article-title":"Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.","volume":"23","author":"Scheen","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.beem.2008.10.002","article-title":"The role of the endocannabinoid system in lipogenesis and fatty acid metabolism.","volume":"23","author":"Vettor","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"R18-16-20210128","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","article-title":"The endocannabinoid system in obesity and type 2 diabetes.","volume":"51","author":"Di Marzo","year":"2008","journal-title":"Diabetologia"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000115362","article-title":"Role of the endocannabinoid system in energy balance regulation and obesity.","volume":"36","author":"Cota","year":"2008","journal-title":"Front Horm Res"},{"issue":"8","key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/oby.2009.84","article-title":"Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.","volume":"17","author":"Cota","year":"2009","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"R21-16-20210128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1734-1140(09)70025-8","article-title":"Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.","volume":"61","author":"Leite","year":"2009","journal-title":"Pharmacol Rep"},{"issue":"suppl 2","key":"R22-16-20210128","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.2337\/dc08-s258","article-title":"Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.","volume":"31","author":"Van Gaal","year":"2008","journal-title":"Diabetes Care"},{"issue":"4","key":"R23-16-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00213-009-1612-6","article-title":"Role of cannabis and endocannabinoids in the genesis of schizophrenia.","volume":"206","author":"Fernandez-Espejo","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"R24-16-20210128","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00406-009-0028-y","article-title":"The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders.","volume":"259","author":"Galve-Roperh","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"25","key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R27-16-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale.","volume":"22","author":"Addington","year":"1993","journal-title":"Br J Psychiatry Suppl"},{"issue":"1","key":"R28-16-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.psychres.2005.10.002","article-title":"Diagnostic validity of assessment scales for depression in patients with schizophrenia.","volume":"144","author":"Kim","year":"2006","journal-title":"Psychiatry Res"},{"issue":"1","key":"R29-16-20210128","first-page":"66","article-title":"Assessment of capacity to give consent to research participation: state-of-the-art and beyond.","volume":"1","author":"DeRenzo","year":"1998","journal-title":"J Health Care Law Policy"},{"issue":"79","key":"R30-16-20210128","first-page":"812","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"issue":"10","key":"R31-16-20210128","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"2","key":"R32-16-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.v66n0208","article-title":"Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.","volume":"66","author":"Brar","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R33-16-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R34-16-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R35-16-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/schbul\/sbm152","article-title":"Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.","volume":"34","author":"McMahon","year":"2008","journal-title":"Schizophr Bull"},{"issue":"6","key":"R37-16-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"R38-16-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"R39-16-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.expneurol.2010.03.018","article-title":"The endocannabinoid system and psychiatric disorders.","volume":"224","author":"Parolaro","year":"2010","journal-title":"Exp Neurol"},{"issue":"2","key":"R40-16-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant.","volume":"31","author":"Moreira","year":"2009","journal-title":"Rev Bras Psiquiatr"},{"issue":"3","key":"R41-16-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.drugalcdep.2009.07.002","article-title":"The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.","volume":"105","author":"Ward","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"R42-16-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.2005.00540.x","article-title":"The role of dopamine in reward and pleasure behaviour-review of data from preclinical research.","volume":"427","author":"Bressan","year":"2005","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"4","key":"R43-16-20210128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.fbp.0000135704.56422.40","article-title":"CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.","volume":"15","author":"Haller","year":"2004","journal-title":"Behav Pharmacol"},{"issue":"4","key":"R44-16-20210128","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00213-009-1494-7","article-title":"Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats.","volume":"204","author":"Haller","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"R45-16-20210128","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.phrs.2007.09.006","article-title":"The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction.","volume":"56","author":"Lafenetre","year":"2007","journal-title":"Pharmacol Res"},{"issue":"6","key":"R46-16-20210128","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/156802609788897844","article-title":"The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.","volume":"9","author":"Lee","year":"2009","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"R47-16-20210128","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","article-title":"Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.","volume":"312","author":"Le Foll","year":"2005","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318204825b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:58:49Z","timestamp":1620957529000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201102000-00016"}},"subtitle":["A Randomized, Double-Blind, Pilot Study"],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318204825b","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}